ECSP18062614A - Moléculas que activan selectivamente las células t reguladoras para el tratamiento de enfermedades autoinmunes - Google Patents

Moléculas que activan selectivamente las células t reguladoras para el tratamiento de enfermedades autoinmunes

Info

Publication number
ECSP18062614A
ECSP18062614A ECSENADI201862614A ECDI201862614A ECSP18062614A EC SP18062614 A ECSP18062614 A EC SP18062614A EC SENADI201862614 A ECSENADI201862614 A EC SENADI201862614A EC DI201862614 A ECDI201862614 A EC DI201862614A EC SP18062614 A ECSP18062614 A EC SP18062614A
Authority
EC
Ecuador
Prior art keywords
cells
molecules
treatment
protein
autoimmune diseases
Prior art date
Application number
ECSENADI201862614A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP18062614A publication Critical patent/ECSP18062614A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)

Abstract

Proteína de fusión que comprende una proteína agonista selectiva de IL2αβγ (agonista selectivo de IL2) y una proteína IgG Fc unidas a través de un conector. La unidad agonista selectiva de IL2 presenta actividad terapéutica al activar selectivamente la forma del receptor IL2αβγ, con lo que puede estimular selectivamente las células T reguladoras. La unidad Fc provee una vida media en la circulación más prolongada que la de una proteína IL-2 o IL2SA.
ECSENADI201862614A 2016-01-20 2018-08-20 Moléculas que activan selectivamente las células t reguladoras para el tratamiento de enfermedades autoinmunes ECSP18062614A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15/002,144 US20170204154A1 (en) 2016-01-20 2016-01-20 Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
ECSP18062614A true ECSP18062614A (es) 2018-10-31

Family

ID=59314394

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201862614A ECSP18062614A (es) 2016-01-20 2018-08-20 Moléculas que activan selectivamente las células t reguladoras para el tratamiento de enfermedades autoinmunes

Country Status (16)

Country Link
US (7) US20170204154A1 (es)
EP (1) EP3405482A4 (es)
JP (2) JP6983787B2 (es)
KR (1) KR20180100237A (es)
CN (1) CN108602871A (es)
AU (2) AU2017210187B2 (es)
BR (1) BR112018014671A2 (es)
CA (1) CA3010621A1 (es)
CL (1) CL2018001951A1 (es)
CO (1) CO2018008558A2 (es)
EA (1) EA201891656A1 (es)
EC (1) ECSP18062614A (es)
MX (1) MX2018008840A (es)
SG (1) SG11201805784PA (es)
WO (1) WO2017127514A1 (es)
ZA (1) ZA201804458B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016014428A2 (en) * 2014-07-21 2016-01-28 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
SG11201903882VA (en) * 2016-11-08 2019-05-30 Delinia Inc Il-2 variants for the treatment of autoimmune diseases
JP7165717B2 (ja) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド 標的免疫寛容
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
CA3115461A1 (en) * 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
AU2019233576A1 (en) 2018-03-13 2020-09-17 Cancer Research Technology Limited Anti-CD25 for tumour specific cell depletion
KR102824112B1 (ko) 2018-03-28 2025-06-24 브리스톨-마이어스 스큅 컴퍼니 인터루킨-2/인터루킨-2 수용체 알파 융합 단백질 및 사용 방법
CN112534052B (zh) 2018-07-25 2024-09-20 奥美药业有限公司 全新il-21前药及使用方法
KR20210055694A (ko) 2018-08-06 2021-05-17 메디카인 인코포레이티드 Il-2 수용체 결합 화합물
MX2021003543A (es) 2018-09-27 2021-06-23 Xilio Dev Inc Polipeptidos de citocinas enmascaradas.
SG11202104120VA (en) * 2018-10-31 2021-05-28 Delinia Inc Multivalent regulatory t cell modulators
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
WO2020252264A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
KR20220044834A (ko) * 2019-08-15 2022-04-11 사이팀 테라퓨틱스, 인크. 변형된 인터루킨 2 (il-2) 폴리펩타이드, 컨쥬게이트 및 이의 용도
US20230057622A1 (en) * 2019-09-16 2023-02-23 Zensun (Shanghai) Science & Technology, Co., Ltd. Recombinant Human Neuregulin Derivatives and Use Thereof
KR20220110207A (ko) 2019-11-05 2022-08-05 메디카인 인코포레이티드 IL-2RβγC 결합 화합물
IL292803A (en) 2019-11-05 2022-07-01 Medikine Inc Dual il-2 receptor and il-7 receptor binding compounds, compositions comprising same and uses thereof
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
JP2023514010A (ja) 2020-01-10 2023-04-05 ブライト ピーク セラピューティクス エージー 修飾ｉｌ－２ポリペプチドおよびその使用
JP7767290B2 (ja) 2020-01-11 2025-11-11 アスクジーン・ファーマ・インコーポレイテッド 新規なマスクされたサイトカインおよびその使用方法
CA3169452A1 (en) 2020-02-03 2021-08-12 Medikine, Inc. Il-7r.alpha. binding compounds
US11746139B2 (en) 2020-02-03 2023-09-05 Medikine, Inc. IL-7Rαγc binding compounds
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
JP2023526282A (ja) 2020-05-13 2023-06-21 ボナム セラピューティクス，インク． タンパク質複合体の組成物及びその使用方法
TW202406932A (zh) * 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
MX2023005030A (es) 2020-10-29 2023-05-16 Bristol Myers Squibb Co Proteinas de fusion para el tratamiento de enfermedades.
JP2023553323A (ja) 2020-11-25 2023-12-21 エクシリオ デベロップメント， インコーポレイテッド 腫瘍特異的に切断可能なリンカー
AU2021391924A1 (en) 2020-12-04 2023-06-22 The General Hospital Corporation Methods of using interleukin-2 agents
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
CN113789346A (zh) * 2021-08-25 2021-12-14 北京伟德杰生物科技有限公司 长效化重组人白细胞介素2融合蛋白及其制备方法和应用
MX2024009868A (es) * 2022-02-11 2024-08-20 Visterra Inc Muteinas de interleucina-2 para el tratamiento de enfermedades autoinmunitarias.
US11999771B2 (en) 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins
CN115322260B (zh) * 2022-06-13 2026-02-10 杭州高田生物医药有限公司 能够在肠道内富集且增殖调节性t细胞的融合蛋白及应用
WO2024054868A1 (en) * 2022-09-07 2024-03-14 Xencor, Inc. An il-2 fc fusion protein for use in methods for the treatment of plaque psoriasis and atopic dermatitis
CN121002050A (zh) * 2023-02-21 2025-11-21 艾诺康医药公司 编码经修饰的白细胞介素2（il2）多肽的多核苷酸以及其制备和使用方法

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5466447A (en) 1988-06-29 1995-11-14 Amgen Inc. Method for treating psoriasis
WO1990000565A1 (en) 1988-07-05 1990-01-25 Amgen Inc. Interleukin ii analogs
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
AU5134693A (en) 1993-09-21 1995-04-10 Amgen, Inc. Method for treating psoriasis
CN1204147C (zh) 1998-02-25 2005-06-01 利思进药品公司 提高以抗体为基础的融合蛋白的循环半衰期的方法
FI104522B (fi) 1998-04-28 2000-02-15 Abb Control Oy Kytkinvarokerunko
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6348192B1 (en) 1999-05-11 2002-02-19 Bayer Corporation Interleukin-2 mutein expressed from mammalian cells
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
DE60138222D1 (de) 2000-09-14 2009-05-14 Beth Israel Hospital Modulierung von il-2 und il-15 vermittelten t zellantworten
HUP0303428A2 (hu) 2001-03-07 2004-01-28 Merck Patent Gmbh. Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez
ATE468862T1 (de) 2001-07-11 2010-06-15 Maxygen Inc G-csf konjugate
US7314712B2 (en) 2001-07-27 2008-01-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Systems for in vivo site-directed mutagenesis using oligonucleotides
WO2003015697A2 (en) 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
ATE542137T1 (de) 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
US7452968B2 (en) 2003-01-02 2008-11-18 University Of Southern California Secreted protein factor and cell membrane-bound splice variant
JP4629047B2 (ja) 2003-06-12 2011-02-09 イーライ リリー アンド カンパニー Ｇｌｐ−１アナログ複合タンパク質
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
DE602004031681D1 (de) 2003-07-21 2011-04-14 Transgene Sa Multifunktionelle Cytokine
ATE554108T1 (de) 2003-07-25 2012-05-15 Amgen Inc Verfahren bezüglich ldcam und crtam
EP1723251A4 (en) 2004-03-05 2008-04-23 Novartis Vaccines & Diagnostic IN VITRO TEST SYSTEM FOR THE FORECASTING THE COMPATIBILITY OF A PATIENT AGAINST THERAPEUTICS
ES2432141T3 (es) 2005-01-27 2013-11-29 Novartis Vaccines And Diagnostics, Inc. Procedimientos para tratar carcinoma de células renales
PL1688146T3 (pl) 2005-02-07 2007-12-31 Novartis Vaccines & Diagnostics Inc Przygotowywanie aldesleukiny do zastosowania farmaceutycznego
HUE028379T2 (en) * 2006-09-29 2016-12-28 Oncomed Pharm Inc Preparations and procedures for the diagnosis and treatment of cancer
FR2918770B1 (fr) 2007-07-10 2009-09-11 Essilor Int Afficheur destine a etre integre a une paire de lunettes.
US8906356B2 (en) 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
US20110274650A1 (en) * 2009-01-21 2011-11-10 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
SG10201402742YA (en) 2009-03-20 2014-08-28 Genentech Inc Bispecific anti-her antibodies
MX2011013457A (es) 2009-06-15 2012-05-08 Biokine Therapeutics Ltd Polipeptidos que enlazan quimioquina novedosos capaces de inhibir el curso de autoinmunidad, inflamacion y cancer.
PT2542590T (pt) 2010-03-05 2017-08-31 Univ Johns Hopkins Composições e métodos para anticorpos e proteínas de fusão imunomoduladores direcionados
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
KR102591732B1 (ko) 2010-11-12 2023-10-19 넥타르 테라퓨틱스 Ｉｌ-2 부분 및 중합체의 접합체
CN102462837B (zh) 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
WO2012088446A1 (en) 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
CN102174111B (zh) 2011-01-25 2013-01-09 江苏省弗泰生物科技有限公司 人白介素2-Fc融合蛋白及其用途
HUE029139T2 (hu) 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
ES2811624T3 (es) 2011-03-11 2021-03-12 Hopitaux Paris Assist Publique Régimen de dosificación de IL-2 para tratar lupus eritematoso sistémico
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
JP2014094898A (ja) * 2012-11-07 2014-05-22 Univ Of Tsukuba 炎症性腸疾患に関連する、ＣＤ３００ａ発現細胞の活性調節剤を含有する医薬品、ならびにＣＤ３００ａ遺伝子欠損マウスおよびＣＤ３００ａ発現細胞の活性調節剤の使用
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
EP2970486B1 (en) * 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
CN103193887B (zh) 2013-04-03 2015-02-04 江苏众红生物工程创药研究院有限公司 一种重组猪白细胞介素2-Fc融合蛋白及其编码基因和表达方法
US20150017120A1 (en) 2013-06-13 2015-01-15 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
RS58149B1 (sr) 2014-02-06 2019-02-28 Hoffmann La Roche Fuzioni proteini interleukina-2 i njihova upotreba
US10150802B2 (en) 2014-04-24 2018-12-11 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
KR20150133576A (ko) 2014-05-20 2015-11-30 삼성전자주식회사 화학적 개질된 표적화 단백질 및 그의 이용
WO2016014428A2 (en) 2014-07-21 2016-01-28 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
SI3482766T1 (sl) 2014-08-11 2020-09-30 Delinia, Inc. Spremenjene variante IL-2, ki selektivno aktivirajo regulatorne T celice za zdravljenje avtoimunskih bolezni
WO2016025647A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
US10806773B2 (en) 2014-10-09 2020-10-20 Dana-Farber Cancer Institute, Inc. Multiple-variable IL-2 dose regimen for treating immune disorders
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CN115073581A (zh) 2016-05-04 2022-09-20 美国安进公司 用于扩增t调节性细胞的白细胞介素-2突变蛋白
SG11201903882VA (en) 2016-11-08 2019-05-30 Delinia Inc Il-2 variants for the treatment of autoimmune diseases

Also Published As

Publication number Publication date
US20190202882A1 (en) 2019-07-04
CO2018008558A2 (es) 2018-08-21
US10875901B2 (en) 2020-12-29
EP3405482A4 (en) 2019-06-26
JP2019507589A (ja) 2019-03-22
MX2018008840A (es) 2018-11-09
US20190153058A1 (en) 2019-05-23
KR20180100237A (ko) 2018-09-07
JP2022058337A (ja) 2022-04-12
EA201891656A1 (ru) 2018-12-28
AU2017210187B2 (en) 2021-10-07
WO2017127514A1 (en) 2017-07-27
US20200115429A1 (en) 2020-04-16
JP6983787B2 (ja) 2021-12-17
AU2017210187A1 (en) 2018-07-19
US10294287B2 (en) 2019-05-21
US20180037624A1 (en) 2018-02-08
CN108602871A (zh) 2018-09-28
US10766938B2 (en) 2020-09-08
US20170204154A1 (en) 2017-07-20
AU2021257949A1 (en) 2021-11-25
US20190202881A1 (en) 2019-07-04
BR112018014671A2 (pt) 2018-12-11
SG11201805784PA (en) 2018-08-30
US10774126B2 (en) 2020-09-15
US11535657B2 (en) 2022-12-27
CA3010621A1 (en) 2017-07-27
EP3405482A1 (en) 2018-11-28
ZA201804458B (en) 2019-09-25
CL2018001951A1 (es) 2018-12-28
US20210070828A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
CO2018008558A2 (es) Moléculas que activan selectivamente las células t reguladoras para el tratamiento de enfermedades autoinmunes
MX378790B (es) Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes.
MX2017014822A (es) Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
CO2018002450A2 (es) Proteínas de fusión de gitrl y usos de las mismas
MX2017000833A (es) Variantes il-2 modificadas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunitarias.
CO2019007868A2 (es) Anticuerpos agonistas anti-icos y sus usos
UY36021A (es) Proteìnas fc multimèricas
MX2021001837A (es) Constructos del receptor de celulas t y usos de los mismos.
PL3559034T3 (pl) Terapia skojarzona dwuswoistymi przeciwciałami anty-CD20/anty-CD3 i agonistami 4-1BB (CD137)
DOP2017000258A (es) Proteínas de fusión
BR112019007100A2 (pt) composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
CR20160333A (es) Proteinas de fusión de interleucina-2 y usos de las mismas
SA517380842B1 (ar) بروتينات دمج لمستقبل إنترليوكين-2/إنترليوكين-2 ألفا وطرق الاستخدام
MX2017002605A (es) Receptores de antigeno quimerico condicionalmente activos para celulas t modificadas.
BR112016024515A2 (pt) proteínas do agonista do receptor trail de cadeia única
CL2018002495A1 (es) Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización en inmunoterapia contra el cáncer. (divisional solicitud 201600227)
ECSP20032306A (es) Análogos de incretina y sus usos
CY1124727T1 (el) Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων
MX373805B (es) Agonistas de receptor fgf21 y usos del mismo.
MX2018009499A (es) Anticuerpos monoclonales especificos de egfl6 y metodos de su uso.
BR112019011461A2 (pt) terapia celular à base de nk melhorada
AR113220A1 (es) Anticuerpos agonistas anti-icos y sus usos
UY35622A (es) Moduladores de los receptores de estrógeno y sus usos